Literature DB >> 14981208

Economics and obesity: costing the problem or evaluating solutions?

Larissa Roux1, Cam Donaldson.   

Abstract

There is no doubt that obesity is a major public health problem. However, what is the contribution of economics to solving it? In this report, we make the case that the role of economics is not in measuring the economic burden of obesity, through so-called cost-of-illness studies. Such studies merely confirm that obesity is a serious societal issue; adding a monetary figure to this does not add much. The economic foundations of such estimates can also be questioned, thus lessening their policy relevance. The real value of economics in the arena of obesity care is in evaluating, through formal economic evaluation, the use of our scarce health care resources in different strategies to prevent and treat obesity.

Entities:  

Mesh:

Year:  2004        PMID: 14981208     DOI: 10.1038/oby.2004.23

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  14 in total

1.  Cost-of-illness studies: a guide to critical evaluation.

Authors:  Allison Larg; John R Moss
Journal:  Pharmacoeconomics       Date:  2011-08       Impact factor: 4.981

2.  Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy.

Authors:  Eberhard Wille; Jürgen Scholze; Eduardo Alegria; Claudio Ferri; Sue Langham; Warren Stevens; David Jeffries; Kerstin Uhl-Hochgraeber
Journal:  Eur J Health Econ       Date:  2010-04-20

Review 3.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review.

Authors:  A G Tsai; D F Williamson; H A Glick
Journal:  Obes Rev       Date:  2011-01       Impact factor: 9.213

4.  The impact of obesity on health care costs among persons with schizophrenia.

Authors:  Lydia A Chwastiak; Robert A Rosenheck; Joseph P McEvoy; T Scott Stroup; Marvin S Swartz; Sonia M Davis; Jeffrey A Lieberman
Journal:  Gen Hosp Psychiatry       Date:  2008-10-23       Impact factor: 3.238

Review 5.  Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?

Authors:  Craig M Smith; Andrew W Walker; Ihaia T Hosken; Berenice E Chua; Cary Zhang; Mouna Haidar; Andrew L Gundlach
Journal:  Front Pharmacol       Date:  2014-03-21       Impact factor: 5.810

6.  Cost analyses of obesity in Canada: scope, quality, and implications.

Authors:  Stefan Kuhle; Arto Ohinmaa; Bach Xuan Tran; Amrita V Nair; Paul J Veugelers
Journal:  Cost Eff Resour Alloc       Date:  2013-02-08

7.  Lifetime medical costs of obesity: prevention no cure for increasing health expenditure.

Authors:  Pieter H M van Baal; Johan J Polder; G Ardine de Wit; Rudolf T Hoogenveen; Talitha L Feenstra; Hendriek C Boshuizen; Peter M Engelfriet; Werner B F Brouwer
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

8.  The cost-effectiveness of a school-based overweight program.

Authors:  Henry Shelton Brown; Adriana Pérez; Yen-Peng Li; Deanna M Hoelscher; Steven H Kelder; Roberto Rivera
Journal:  Int J Behav Nutr Phys Act       Date:  2007-10-01       Impact factor: 6.457

9.  Valuing human leptospirosis prevention using the opportunity cost of labor.

Authors:  Joseph Arbiol; Maridel Borja; Mitsuyasu Yabe; Hisako Nomura; Nina Gloriani; Shin-ichi Yoshida
Journal:  Int J Environ Res Public Health       Date:  2013-05-03       Impact factor: 3.390

Review 10.  Economics of obesity--learning from the past to contribute to a better future.

Authors:  Jaithri Ananthapavan; Gary Sacks; Marj Moodie; Rob Carter
Journal:  Int J Environ Res Public Health       Date:  2014-04-14       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.